Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin62
Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report53
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria50
Total marrow irradiation as part of autologous stem cell transplantation for patients with multiple myeloma49
Income and education affect prognosis and treatment in symptomatic myeloma43
The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma41
Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis38
Tumor microenvironment as a novel therapeutic target for lymphoid leukemias37
Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia36
Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries36
TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy35
The value of prognostic nutritional index in nasal-type, extranodal natural killer/T-cell lymphoma35
High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia34
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update33
Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia29
CMV infection is a risk factor for hemorrhagic cystitis after hematopoietic stem cell transplantation29
Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration28
Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study27
Ruxolitinib for pediatric acute and chronic graft-versus-host disease: a single-center retrospective study of efficacy and safety26
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations25
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study25
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis24
COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses23
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab23
0.070998907089233